Cytokines and therapy in COPD: A promising combination?

Chest

Volumn 121, Issue 5 SUPPL., 2002, Pages 209S-218S

  De Boer, W I ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Antagonists; Chemokines; COPD; Cytokines; Interleukin 8; Monocyte chemoattractant protein 1; Receptors; Therapy; Tumor necrosis factor

Indexed keywords

CYTOKINE; GLUCOCORTICOID; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN; PROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

BIOAVAILABILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DISEASE ASSOCIATION; ENZYME RELEASE; GOBLET CELL; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LUNG ALVEOLUS WALL; LUNG FUNCTION; MACROPHAGE; METAPLASIA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REDUCTION;

EID: 0036261088     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (123)

1. Differences and similarities between chronic obstructive pulmonary disease and asthma
2. Up-regulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis
3. Chronic obstructive pulmonary disease: The role of bronchiolar mast cells and macrophages
4. 1
5. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis
6. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease
7. Severity of airflow limitation is associated with severity of airway inflammation in smokers
8. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease
9. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation
10. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease
11. Corticosteroid reversibility in COPD is related to features of asthma
12. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis
13. Inhaled fluticasone propionate (FP) reduces the number of inflammatory cells in bronchial biopsies of COPD patients with bronchial hyperresponsiveness (BHR)
14. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial
15. Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury
16. MMP-2 and MMP-9-linked gelatonolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease
17. Neutrophils and protease/antiprotease imbalance
18. Predominant Th1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease
19. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
20. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels
21. Chemokines in allergy
22. International Union of Pharmacology: XXII. Nomenclature for chemokine receptors
23. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease
24. Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction
25. Physical association and functional antagonism between the p65 subunit of transcription factor NF-3B and the glucocorticoid receptor
26. Role of transcriptional activation of IκBα in mediation of immuno-suppression by glucocorticoids
27. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells
28. Molecular mechanisms of glucocorticoid action: What is important?
29. Increased MCP-1 and MIP-1β in bronchoalveolar lavage fluid of chronic bronchitics
30. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD
31. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
32. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue to smoke
33. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
34. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease; a randomised controlled trial
35. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease
36. Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers
37. Adverse effects of corticoid therapy for COPD: A critical review
38. Glucocorticoid-regulated gene expression during cutaneous wound repair
39. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema
40. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis
41. Increased resting energy expenditure is related to plasma TNF-α concentration in stable COPD patients
42. Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells
43. Tumor necrosis factor-α gene polymorphism in chronic bronchitis
44. A polymorphism in the tumor necrosis factor-α gene promoter region may predispose to a poor prognosis in COPD
45. Association of tumor necrosis factor α gene promoter polymorphism with the presence of chronic obstructive pulmonary disease
46. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcription activation
47. Stimulation of neutrophils by tumor necrosis factor
48. Tumor necrosis factor β (lymphotoxin) inhibits locomotion and stimulates the respiratory burst and degranulation of neutrophils
49. Effect of tumor necrosis factor and granulocyte/macrophage colony-stimulating factor on neutrophil degranulation
50. Epidermal growth factor system regulates mucin production in airways
51. Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke
52. Tumor necrosis factor-α (TNFα) regulates the epithelial barrier in the human intestinal cell line HT-29/B6
53. Effects of TNF-α, IFN-γ, and IL-1β on normal human bronchial epithelial cells
54. Expression of a tumor necrosis factor α transgene in murine lung causes lymphocytic and fibrosing alveolitis: A mouse model of progressive pulmonary fibrosis
55. Tumor necrosis factor-α induces emphysema-like pulmonary tissue rebuilding: Changes in type II alveolar epithelial cells
56. Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells
57. Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1β and tumor necrosis factor-α
58. IL-6, IL-8 and TNF production by cytokine and lipopolysaccharide-stimulated human renal cortical epithelial cells in vitro
59. Tumor necrosis factor α modulates the expression of its p60 receptor and several cytokines in rat tracheal epithelial cells
60. Interferon-γ induced cell death in a cultured human salivary gland cell line
61. Interferon γ induction of pulmonary emphysema in the adult murine lung
62. Pathogenesis of Crohn's disease
63. Cytokine blockade as a new strategy to treat rheumatoid arthritis: Inhibition of tumor necrosis factor
64. Infliximab and methotrexate in the treatment of rheumatoid arthritis
65. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor-α blockade in patients with rheumatoid arthritis
66. Crohn's disease associated with spondylo-arthropathy: Effect of TNFα blockade with infliximab on articular symptoms
67. Antibodies to tumor necrosis factor α as treatment for Crohn's disease
68. Biologic therapy for rheumatoid arthritis
69. Effect of a chimeric antibody to tumor necrosis factor α on cytokine and physiologic responses in patients with severe sepsis: A randomized, clinical trial
70. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
71. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
72. Constitutive and stimulated MCP-1, GROα, β, and γ expression in human airway epithelium and bronchoalveolar macrophages
73. Smoke extract stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activities
74. Dexamethasone inhibits tumor necrosis factor-α-induced expression of macrophage inflammatory protein-2 and adhesion of neutrophils to endothelial cells
75. Human granulocyte chemotactic peptide (IL-8) as a specific neutrophil degranulator: Comparison with other monokines
76. A comparison of post-receptor signal transduction events in Jurkat cells transfected with either IL-8R1 or IL-8R2 chemokine mediated activation of p42/p44 MAP-kinase (ERK-2)
77. Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2
78. Chemokine antagonists that discriminate between interleukin-8 receptors
79. Inhibition of neutrophil-mediated acute inflammatory injury by an antibody against interleukin-8 (IL-8)
80. Identification of a potent, selective non-peptide CXCR2 antagonists that inhibits interleukin-8-induced neutrophil migration
81. Tumor necrosis factor α regulates CXC chemokine receptor expression and function
82. Inhibition of murine neutrophil recruitment in vivo by CXC chemokine receptor antagonists
83. Acid aspiration-induced lung injury in rabbits is mediated by interleukin-8-dependent mechanisms
84. Delayed wound healing in CXCR2 knockout mice
85. Interleukin-8 receptor-mediated chemotaxis of normal human epithelial cells
86. Interleukin-8: A corneal factor that induces neovascularization
87. Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation
88. Distributions of melanoma growth stimulatory activity or growth-regulated gene and the interleukin-8 receptor B in human wound repair
89. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice
90. Pulmonary expression of interleukin 8 and its receptor CXCR2 in chronic obstructive pulmonary disease
91. Chemokine receptor expression by human intestinal epithelial cells
92. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells
93. Interleukin-8 stimulates the migration of human colonic epithelial cells in vitro
94. Chemokines IL-8, GRO-α, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing
95. Interleukin-8 mediates injury from smoke inhalation to both the lung endothelial and the alveolar epithelial barriers in rabbits
96. CXCR-2 receptor blockade worsens pulmonary clearance in murine Pseudomonas aeruginosa pneumonia
97. Expression of monocyte chemoattractant protein-1 and interleukin-8 receptors on subsets of T cells: Correlation with transendothelial chemotactic potential
98. Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells
99. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice
100. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor
101. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice
102. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice
103. Monocyte chemotactic protein-1 provokes mast cell aggregation and [3H]5HT release
104. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes
105. Identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK
106. CCR11 is a functional receptor for the monocyte chemoattractant protein family of chemokines
107. Expression and regulation of human pulmonary fibroblast-derived monocyte chemotactic peptide-1
108. Interferon γ induces differential upregulation of α and β chemokine secretion in colonic epithelial cell lines
109. Selective inhibition of expression of the chemokine receptor CCR2 in human monocytes by IFN-γ
110. Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activation
111. The coordinated action of CC chemokines in the lung orchestrate allergic inflammation and airway hyperresponsiveness
112. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice
113. Expression of CCR2 by endothelial cells: Implications for mCP-1 mediated wound injury repair and in vivo inflammatory activation of endothelium
114. Human endothelial cells express CR2 and respond to MCP-1: A direct role of MCP-1 in angiogenesis and tumor progression
115. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries
116. 1 gene expression by monocyte chemoattractant protein-1 via specific receptors
117. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes
118. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues
119. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: Binding to a common chemokine receptor motif within the helical bundle
120. The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2
121. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model
122. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease
123. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes